We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

184 hedge funds and large institutions have $761M invested in Acorda Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 79 increasing their positions, 41 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 41

24% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 21

3% more funds holding

Funds holding: 179 → 184 (+5)

8% less capital invested

Capital invested by funds: $826M → $761M (-$65M)

52% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $5.05M

Holders
184
Holders Change
+5
Holders Change %
+2.79%
% of All Funds
3.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
79
Reduced
41
Closed
21
Calls
$2.4M
Puts
$5.05M
Net Calls
-$2.65M
Net Calls Change
-$26M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$27.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$11.5M
3
State Street
State Street
Massachusetts
+$9.6M
4
Prudential Financial
Prudential Financial
New Jersey
+$6.06M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.08M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$17.3M
2
Invesco
Invesco
Georgia
-$17.1M
3
SCM
Scopia Capital Management
New York
-$15.5M
4
Millennium Management
Millennium Management
New York
-$11M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
151
Elkfork Partners
Oregon
$91K – – –
SDIC
152
South Dakota Investment Council
South Dakota
$78K – – –
RCM
153
Riverhead Capital Management
Delaware
$74K – – –
TAM
154
Tyers Asset Management
Texas
$66K – – –
OAM
155
Oppenheimer Asset Management
New York
$55K +$19.8K +11 +48%
Group One Trading
156
Group One Trading
Illinois
$53K +$59.5K +33 New
AIP
157
Ameritas Investment Partners
Nebraska
$49K – – –
PI
158
PineBridge Investments
New York
$44K -$632K -351 -93%
FGAM
159
Financial Gravity Asset Management
Texas
$44K +$50.4K +28 New
Royal Bank of Canada
160
Royal Bank of Canada
Ontario, Canada
$38K – – –
Bank of Montreal
161
Bank of Montreal
Ontario, Canada
$36K +$9.01K +5 +28%
RA
162
Royce & Associates
New York
$32K +$10.8K +6 +43%
LTFS
163
Ladenburg Thalmann Financial Services
Florida
$30K – – –
Zurich Cantonal Bank
164
Zurich Cantonal Bank
Switzerland
$24K -$19.8K -11 -42%
TRCT
165
Tower Research Capital (TRC)
New York
$20K +$18K +10 +333%
LIA
166
LS Investment Advisors
Michigan
$19K – – –
PNC Financial Services Group
167
PNC Financial Services Group
Pennsylvania
$16K – – –
MOACM
168
Mutual of America Capital Management
New York
$15K +$1.8K +1 +13%
FWM
169
Focused Wealth Management
New York
$13K – – –
AG
170
Advisor Group
Arizona
$13K +$7.21K +4 +80%
MAM
171
Meeder Asset Management
Ohio
$12K -$168K -93 -93%
PHK
172
Point72 Hong Kong
Hong Kong
$12K -$1.8K -1 -11%
VCM
173
Versant Capital Management
Arizona
$9K -$9.01K -5 -45%
CG
174
Cutler Group
California
$9K – – –
SWA
175
Sutton Wealth Advisors
Florida
$7.2K -$1.8K -1 -17%
5 6
7
8 9

ACOR Hedge Fund Activity: Q1 2019 in Review

184 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2019, worth a combined $761M — down 7.9% from $826M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 21 closed out — a net gain of 5 holders — while 79 added to existing stakes and 41 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $27.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $17.3M sold.

  • 184 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2019, up from 179 in Q4 2018.
  • Funds reported $761M of Acorda Therapeutics stock for Q1 2019, down 7.9% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q1 2019 and 21 closed out, a net change of +5 holders.
  • The largest Acorda Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $27.4M added.
  • The largest Acorda Therapeutics seller in Q1 2019 was PFM Health Sciences, an estimated $17.3M sold.

Based on aggregated 13F filings for Q1 2019.